SciLifeLab joins EuCAI

We warmly welcome SciLifeLab, represented by Päivi Östling and Jordi Carreras Puigvert.

AstraZeneca joins EuCAI

EuCAI welcomes Erik Mullers. Erik is a senior scientist at AstraZeneca and he will represent the pharmaceutical industry.

​International scientists call for a rethink on industrial and academic drug discovery

A group of prominent scientists shared their opinion in Nature Reviews Drug Discovery about ineffective academic and industrial drug discovery investments and funding structures. Parallel competitive research and development funding restricted to traditional drug discovery operating models is suggested as one major contributing factor to the exponential increase in the cost of new medicines. The article proposes that early drug discovery efforts would benefit from improved global co-ordination to remove parallel and redundant developments of reusable technologies. The authors also call for a quicker adoption of new technologies and alternative drug discovery strategies to avoid the current high attrition rates in drug development that fail to address the unmet medical needs presented by an aging population. The authors claim new advances in digital microscopy, genome-editing, induced pluripotent stem cell and 3D tissue culture technologies are poised to create more relevant disease-oriented models and a new era of cutting edge drug discovery pipelines. Evolution of traditional drug discovery models could spark modern healthcare revolutions, however, such adaptation may be prohibitively expensive without funding structures, which support global pre-competitive collaboration to advance more innovative drug discovery approaches.​

New member institution   ICGEB - Trieste, Italy

We welcome our new member the International Centre for Genetic Engineering and Biotechnology (ICGEB) - (Trieste, Italy).  >>read  more>>

EuCAI committee meeting in Lausanne

Next committee meeting will be 10-11 June in Lausanne on the Swiss Image-Based Screening Conference.

EuCAI goes to the US

Anthony Davies and Peter Horvath will present EuCAI in Houston TX on the Advanced Models for Imaging-based Drug Screening meeting 14th May. This is the first step towards extending EuCAI to a Transatlantic interest group.

Trinity College Hosts Europe Wide Collaboration of World Leading Innovators and Entrepreneurs in the Field of Automated Cell Biology: eBulletin April 2013 Edition

Dr Anthony Mitchell Davies Director of the Irish National Centre for High Content Screening and Analysis (INCHSA) based in the Institute of Molecular Medicine Trinity College Dublin and Dr Peter Horvath, Ph.D. Head of data analysis, Light Microscopy and Screening Centre ETH Zurich, Switzerland have recently initiated a Europe wide collaboration of world leading innovators and entrepreneurs in the field of automated cell biology. >> read more >>
TCD School of Medicine EBulletin, Apr 02. 2013.